0O9B Stock Overview
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Almirall, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.35 |
| 52 Week High | €10.08 |
| 52 Week Low | €7.20 |
| Beta | 0.38 |
| 1 Month Change | 4.15% |
| 3 Month Change | 15.04% |
| 1 Year Change | 7.59% |
| 3 Year Change | -37.54% |
| 5 Year Change | -40.48% |
| Change since IPO | -39.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0O9B | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -4.3% | 1.9% | 0.5% |
| 1Y | 7.6% | 10.1% | 6.4% |
Return vs Industry: 0O9B underperformed the UK Pharmaceuticals industry which returned 10.1% over the past year.
Return vs Market: 0O9B exceeded the UK Market which returned 6.4% over the past year.
Price Volatility
| 0O9B volatility | |
|---|---|
| 0O9B Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0O9B has not had significant price volatility in the past 3 months.
Volatility Over Time: 0O9B's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 1,904 | Carlos Gallardo Piqué | www.almirall.com |
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.
Almirall, S.A. Fundamentals Summary
| 0O9B fundamental statistics | |
|---|---|
| Market cap | €1.95b |
| Earnings (TTM) | -€38.77m |
| Revenue (TTM) | €915.09m |
2.1x
P/S Ratio-50.3x
P/E RatioIs 0O9B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0O9B income statement (TTM) | |
|---|---|
| Revenue | €915.09m |
| Cost of Revenue | €245.20m |
| Gross Profit | €669.89m |
| Other Expenses | €708.66m |
| Earnings | -€38.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 22, 2024
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 73.21% |
| Net Profit Margin | -4.24% |
| Debt/Equity Ratio | 23.9% |
How did 0O9B perform over the long term?
See historical performance and comparison